

AlphaLISA® AAV9 Capsid Detection Kit

Product number: AL3182HV/C/F

Research Use Only. Not for use in diagnostic procedures.

Product Information

Application: This kit is designed for the quantitative determination of AAV9 capsid using a

homogeneous no wash AlphaLISA assay.

Kit contents: The kit contains 6 components: AlphaLISA Acceptor beads coated with

anti-AAV9 Antibody, Streptavidin-coated Donor Beads, Biotinylated anti-AAV9 Antibody,

Lyophilized AAV9 empty capsid, 10X HiBlock Buffer and 5X AlphaLISA Lysis buffer.

Sensitivity: Lower Detection Limit (LDL): 2.7E+06 VP/mL

Lower Limit of Quantification (LLOQ): 9.7E+06 VP/mL

EC₅₀: 2.3E+10 VP/mL

Dynamic Range: 2.7E+06 – 1.0E+11 VP/mL




Figure 1. Typical sensitivity curve in AlphaLISA HiBlock Buffer. The data was generated using a gray AlphaPlateTM-384 microplate and the EnVision® Multilabel Plate Reader 2102 with Alpha option.

Storage: Store kit in the dark at 4 °C. For reconstituted analyte, aliquot and store at -80 °C for up

to 1 month. Avoid freeze-thaw cycles.

Stability: This kit is stable for at least 12 months from the date of manufacture when stored in its

original packaging and the recommended storage conditions.

Analyte of Interest

Adeno-associated virus serotype 9 (AAV9) is a single-stranded DNA virus with a genome of approximately 4.7 kilobases. This virus needs co-infection with helper viruses such as adenovirus or herpes virus to replicate. AAVs are used as vectors for gene delivery mainly because of their ability to infect cells without pathogenicity and their ease of engineering and production. Serotype 9 used as a vector in gene therapy has been particularly developed for the treatment of neurological diseases mainly because of its ability to cross the blood-brain barrier to target the central nervous system (astrocytes and neurons). It also exhibits a tropism for other tissues such as liver, muscle or lung. The optimization of AAV vectors for their use in clinical trials places AAVs as a promising gene therapy tool. The AlphaLISA AAV9 Capsid Detection Kit is designed to detect and quantify AAV9 particles (being expressed in Viral Particles/mL or VP/mL) in both cell lysates and cell culture media.

Description of the AlphaLISA Assay

AlphaLISA technology allows for the detection of molecules of interest in cell culture media (such as DMEM) and cell lysates in a highly sensitive, quantitative, reproducible and user-friendly mode. In this AlphaLISA assay, a biotinylated anti-AAV9 antibody binds to the Streptavidin coated AlphaLISA Donor Beads, while the anti-AAV9 antibody is conjugated to AlphaLISA Acceptor Beads. In the presence of AAV9 capsid, the beads come into close proximity. The excitation of the Donor Beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer within the Acceptor Beads, resulting in emission with λ_{max} at 615 nm (Figure 2).




Figure 2. AlphaLISA AAV9 Capsid Detection Assay Principle.

Precautions

- The Alpha Donor beads are light-sensitive. All the other assay reagents can be used under normal light conditions. All Alpha assays using the Donor beads should be performed under subdued laboratory lighting (< 100 lux). Green filters (LEE 090 filters (preferred) or Roscolux filters #389 from Rosco) can be applied to light fixtures.
- Take precautionary measures to avoid contamination of the reagent solutions.
- The biotinylated anti-AAV9 antibody contains sodium azide. Contact with skin or inhalation should be avoided.

Kit Content: Reagents and Materials

Kit components	AL3182HV 100 assay points****	AL3182C 500 assay points****	AL3182F 5000 assay points****
AlphaLISA Anti-AAV9 Acceptor beads stored in PBS, 0.05% Kathon CG/ICP, pH 7.2	10 μL @ 5 mg/mL (1 brown tube, <u>white</u> cap)	25 μL @ 5 mg/mL (1 brown tube, <u>white</u> cap)	250 μL @ 5 mg/mL (1 brown tube, <u>white</u> cap)
Streptavidin (SA)-coated Donor beads stored in 25 mM HEPES, 100 mM NaCl, 0.05% Kathon CG/ICP, pH 7.4	40 μL @ 5 mg/mL	200 μL @ 5 mg/mL (1 brown tube, <u>black</u> cap)	1 000 μL @ 5 mg/mL (2 brown tubes, <u>black</u> cap)
Biotinylated Anti-AAV9 Antibody stored in PBS, 0.1% Tween-20, 0.05% NaN ₃ , pH 7.4		100 μL @ 500 nM (1 tube, <u>black</u> cap)	1 000 μL @ 500 nM (1 tube, <u>black</u> cap)
Lyophilized AAV9 empty capsid*	1E+11 VP (1 tube, <u>clear</u> cap)	1E+11 VP (1 tube, <u>clear</u> cap)	1E+11 VP (1 tube, <u>clear</u> cap)
AlphaLISA HiBlock Buffer (10X)**	2 mL, 1 small bottle	10 mL, 1 small bottle	100 mL, 1 large bottle
AlphaLISA Lysis Buffer (5X)***	2 mL, 1 small bottle	10 mL, 1 small bottle	100 mL, 1 large bottle

Reconstitute lyophilized analyte in 100 μ L Milli-Q® grade H2O. The reconstituted analyte should be used within 60 minutes or aliquoted into screw-capped 0.5 mL polypropylene vials and stored at -80 °C for future experiments. The aliquoted analyte at -80 °C is stable up to 1 month. Avoid freeze-thaw cycles. One vial contains an amount of analyte sufficient for performing 10 standard curves. Additional vials can be ordered separately (cat # AL3182S).

Extra buffer can be ordered separately (cat # AL004C: 10 mL, cat # AL004F: 100 mL).

Extra buffer can be ordered separately (cat # AL003C: 10 mL, cat # AL003F: 100 mL)

The number of assay points is based on an assay volume of 100 µL in 96-well plates or 50 µL in 384-well assay plates using the kit components at the recommended concentrations.

Sodium azide should **not** be added to the stock reagents. High concentrations of sodium azide (> 0.001% final in the assay) might decrease the AlphaLISA signal. Note that sodium azide from the biotinylated anti-AAV9 antibody stock solution will not interfere with the AlphaLISA signal (0.0001% final in the assay).

Specific additional required reagents and materials:

The following materials are recommended:

Item	Suggested source	Catalog #
TopSeal™-A Plus Adhesive Sealing Film	Revvity Inc.	6050185
EnVision®-Alpha Reader	Revvity Inc.	-

Recommendations

IMPORTANT: PLEASE READ THE RECOMMENDATIONS BELOW BEFORE USE

- The volume indicated on each tube is guaranteed for single pipetting. Multiple pipetting of the reagents may reduce the theoretical amount left in the tube. To minimize loss when pipetting beads, it is preferable not to pre-wet the tip.
- Centrifuge all tubes (including lyophilized analyte) before use to improve recovery of content (2000*g*, 10-15 sec). Re-suspend all reagents by vortexing before use.
- Use Milli-Q® grade H₂O to dilute 10X AlphaLISA HiBlock Buffer, 5X AlphaLISA Lysis buffer and to reconstitute the lyophilized analyte.
- When diluting the standard or samples, <u>change tips</u> between each standard or sample dilution. When loading reagents in the assay microplate, <u>change tips</u> between each standard or sample addition and after each set of reagents.
- When reagents are added to the microplate, make sure the liquids are at the bottom of the well.
- Small volumes may be prone to evaporation. It is recommended to cover microplates with TopSeal-A Adhesive Sealing Films to reduce evaporation during incubation. Microplates can be read with the TopSeal-A Film in place.
- The AlphaLISA signal is detected with an EnVision Multilabel Plate Reader equipped with the Alpha option using the AlphaScreen standard settings (e.g. Total Measurement Time: 550 ms, Laser 680 nm, Excitation Time: 180 ms, Mirror: D640as, Emission Filter: M570w, Center Wavelength 570 nm, Bandwidth 100 nm, Transmittance 75%).
- AlphaLISA signal will vary with temperature and incubation time. For consistent results, identical incubation times and temperature should be used for each plate.
- The standard curves shown in this technical data sheet are provided for information only. A standard curve must be generated for each experiment.

Assay Procedure

- Two different manuals can be utilized:
 - Manual 1: Default Manual (3 incubation steps) with 10 μL of sample volume: Recommended to obtain the highest assay sensitivity
 - Manual 2: Alternative Manual (3 incubation steps) with 5 μL of sample volume: Recommended when using culture media containing free biotin
- The manual described below is an example for generating one standard curve in a 50 μL final assay volume (48 wells, triplicate determinations). The manuals also include testing samples in 452 wells. If different amount of samples are tested, the volumes of all reagents have to be adjusted accordingly, as shown in the table below. These calculations do not include excess reagent to account for losses during transfer of solutions or dead volumes.
- The standard dilution manual is provided for information only. As needed, the number of replicates or the range of concentrations covered can be modified.
- Use of four background points in triplicate (12 wells) is recommended when LDL/LLOQ is calculated. One background point in triplicate (3 wells) can be used when LDL/LLOQ is not calculated.

			Volume				
Format	# of data points	Final	Sample	AlphaLISA Acceptor Beads	Biotinylated Antibody	SA- Donor beads	Plate recommendation
	50	100 μL	20 µL	20 µL	10 μL	50 μL	White OptiPlate-96 (cat # 6005290)
AL3182HV	100	50 μL	10 μL	10 µL	5 µL	25 μL	½ Area AlphaPlate-96 (cat # 6002350) White OptiPlate-384 (cat # 6007290) Light gray AlphaPlate [™] -384 (cat # 6005350)
	250	100 µL	20 μL	20 µL	10 μL	50 μL	White OptiPlate-96 (cat # 6005290)
AL3182C	500	50 μL	10 μL	10 μL	5 μL	25 μL	½ Area AlphaPlate-96 (cat # 6002350) White OptiPlate-384 (cat # 6007290) Light gray AlphaPlate™-384 (cat # 6005350)
	1 250	20 μL	4 μL	4 µL	2 µL	10 μL	Light gray AlphaPlate-384 (cat # 6005350) ProxiPlate™-384 Plus (cat # 6008280) White OptiPlate-384 (cat # 6007290)
	2 500	10 μL	2 µL	2 μL	1 μL	5 μL	Light gray AlphaPlate-1536 (cat # 6004350)
	5 000	50 μL	10 μL	10 µL	5 μL	25 μL	½ Area AlphaPlate-96 (cat # 6002350) White OptiPlate-384 (cat # 6007290) Light gray AlphaPlate-384 (cat # 6005350)
AL3182F	12 500	20 µL	4 μL	4 µL	2 µL	10 µL	Light gray AlphaPlate-384 (cat # 6005350) ProxiPlate-384 Plus (cat # 6008280) White OptiPlate-384 (cat # 6007290)
	25 000	10 μL	2 µL	2 μL	1 μL	5 μL	Light gray AlphaPlate-1536 (cat # 6004350)

Common Steps for Preparing Reagents (Manuals 1 & 2)

The 3-Steps Manual described below is for 500 assay points including one standard curve (48 wells) and samples (452 wells). If different amount of samples are tested, the volumes of all reagents have to be adjusted accordingly.


- Preparation of AlphaLISA Lysis Buffer 1X (if needed to lyse samples): Add 1 mL of 5X AlphaLISA Lysis Buffer to 4 mL of Milli-Q[®] grade H₂O.
- 2) <u>Preparation of 1X AlphaLISA HiBlock Buffer</u>: Add 5 mL of 10X AlphaLISA HiBlock Buffer to 45 mL Milli-Q[®] grade H₂O.
- 3) Preparation of AAV9 capsid analyte standard dilutions:
 - a. Reconstitute lyophilized AAV9 (1E+11 VP) in 100 μL Milli-Q® grade H2O. Stock AAV9 particles solution concentration is 1E+12 VP/mL. The remaining reconstituted analyte should be aliquoted immediately and stored at -80 °C for future assays (see page 4 for more details).
 - b. Prepare standard dilutions as follows in 1X AlphaLISA HiBlock Buffer (change tip between each standard dilution):

Vol. of AAV9 (μL)		Vol. of diluent (µL) *	[AAV9] in standard curve	
	AAV3 (µL)	undent (µL)	(VP/mL)	
Α	10 µL of reconstituted AAV9	90	1.00E+11*	
В	60 μL of tube A	140	3.00E+10	
С	60 μL of tube B	120	1.00E+10	
D	60 μL of tube C	140	3.00E+9	
E	60 μL of tube D	120	1.00E+9	
F	60 μL of tube E	140	3.00E+8	
G	60 μL of tube F	120	1.00E+8	
Н	60 μL of tube G	140	3.00E+7	
	60 μL of tube H	120	1.00E+7	
J	60 μL of tube I	140	3.00E+6	
K	60 μL of tube J	120	1.00E+6	
L	60 μL of tube K	140	3.00E+5	
M ** (background)	0	100	0	
N ** (background)	0	100	0	
O ** (background)	0	100	0	
P ** (background)	0	100	0	

- * Dilute standards in diluent (e.g. 1X AlphaLISA HiBlock Buffer or 1X AlphaLISA Lysis Buffer). At low concentrations of analyte, a significant amount of analyte can bind to the vial. Therefore, load the analyte standard dilutions in the assay microplate within 60 minutes of preparation.
- ** Four background points in triplicate (12 wells) are used when LDL is calculated. If LDL does not need to be calculated, one background point in triplicate can be used (3 wells).

Manual 1: Default Manual (3 incubation steps) with 10 µL of sample volume: Use of this manual results in higher assay sensitivity


- 4) Preparation of 5X AlphaLISA Anti-AAV9 Antibody Acceptor beads (25 µg/mL):
 - a. Prepare just before use.
 - b. Add 25 μL of 5 mg/mL AlphaLISA Anti-AAV9 Antibody Acceptor Bead to 4975 μL of 1X AlphaLISA HiBlock Buffer.
- 5) Preparation of **10X** biotinylated anti-AAV9 antibody (20 nM):
 - a. Prepare just before use.
 - b. Add 100 µL of 500 nM biotinylated antibody to 2400 µL of 1X AlphaLISA HiBlock Buffer.
- 6) Preparation of 2X Streptavidin (SA) Donor beads (80 µg/mL):
 - a. Prepare just before use.
 - b. Keep the beads under subdued laboratory lighting.
 - c. Add 200 µL of 5 mg/mL SA-Donor beads to 12300 µL of 1X AlphaLISA HiBlock Buffer.
- 7) In a Light Gray AlphaPlate (384 wells):



*CAUTION: The AAV product line will use a sample input volume of 10 μ L instead of the usual 5 μ L. Pay attention to use 10 μ L sample when doing the manual.

Manual 2: Alternative Manual (3 incubation steps) with 5 μL of sample volume: recommended when using culture media containing free biotin

- 3) Preparation of 5X AlphaLISA Anti-AAV9 Antibody Acceptor beads (25 µg/mL):
 - a. Prepare just before use.
 - b. Add 25 μL of 5 mg/mL AlphaLISA Anti-AAV9 Antibody Acceptor Bead to 4975 μL of 1X AlphaLISA HiBlock Buffer.
- 4) Preparation of 5X biotinylated anti-AAV9 antibody (10 nM):
 - a. Prepare just before use.
 - b. Add 100 µL of 500 nM biotinylated antibody to 4900 µL of AlphaLISA HiBlock Buffer.
- 5) Preparation of 2X Streptavidin (SA) Donor beads (80 μg/mL):
 - a. Prepare just before use.
 - b. Keep the beads under subdued laboratory lighting.
 - c. Add 200 µL of 5 mg/mL SA-Donor Beads to 12300 µL of 1X AlphaLISA HiBlock Buffer.
- 6) In a Light Gray AlphaPlate (384 wells):



Data Analysis

- Calculate the average count value for the background wells.
- Generate a standard curve by plotting the AlphaLISA counts versus the concentration of analyte. A log scale can be used for either or both axes. No additional data transformation is required.
- Analyze data according to a nonlinear regression using the 4-parameter logistic equation (sigmoidal dose-response curve with variable slope) and a 1/Y² data weighting (the values at maximal concentrations of analyte after the hook point should be removed for correct analysis).
- The LDL is calculated by interpolating the average background counts (12 wells without analyte) + 3 x standard deviation value (average background counts + (3xSD)) on the standard curve.
- The LLOQ as measured here is calculated by interpolating the average background counts (12 wells without analyte) + 10 x standard deviation value (average background counts + (10xSD)) on the standard curve. Alternatively, the true LLOQ can be determined by spiking known concentrations of analyte in the matrix and measuring the percent recovery, and then determining the minimal amount of spiked analyte that can be quantified within a given limit (usually +/- 20% or 30% of the real concentration).
- Read from the standard curve the concentration of analyte contained in the samples.
- If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

Assay Performance Characteristics

AlphaLISA assay performance described below was determined using the default manual (10 μ L of sample volume and 3-steps manual) using AlphaLISA HiBlock Buffer as assay buffer. The analytes (standards) were prepared in HiBlock Buffer, DMEM, AlphaLISA Lysis Buffer and RPMI. All other components were prepared in HiBlock Buffer.

Assay Sensitivity:

The LDL was calculated as described above. The values correspond to the lowest concentration of analyte that can be detected in a volume of 10 µL sample using the recommended assay conditions.

LDL (VP/mL)	(Analyte diluent)	# of experiments
2.77E+06	AlphaLISA HiBlock Buffer	41
2.42E+06	AlphaLISA Lysis Buffer	5
2.90E+06	DMEM	9
4.44E+07	RPMI (containing free biotin)	7

Assay Precision:

The following assay precision data were calculated from the three independent assays using two different kit lots. In each lot, the analytes were prepared in AlphaLISA HiBlock Buffer, AlphaLISA Lysis Buffer, DMEM or RPMI. All other components were prepared in HiBlock Buffer. Each assay consisted of one standard curve comprising 12 data points (each in triplicate) and 12 background wells (no analytes). The assays were performed in 384-well plate format.

Intra-assay precision:

The intra-assay precision was determined using a total of at least 12 determinations that were interpolated in concentration, data of variability are shown in CV%.

[AAV9]	VP/mL	AlphaLISA HiBlock Buffer	AlphaLISA Lysis Buffer	DMEM	RPMI
CV (9/) Intro	2.00E+09	8%	4%	4%	8%
CV (%) Intra	5.00E+07	11%	8%	11%	N/A

Inter-assay precision:

The inter-assay precision was determined using a total of 3 independent determinations in triplicate that were interpolated in concentration, data of variability are shown in CV%.

[AAV9]	VP/mL	AlphaLISA HiBlock Buffer	AlphaLISA Lysis Buffer	DMEM	RPMI
	1.00E+10	6%	5%	4%	5%
CV (%) Inter	1.00E+09	4%	3%	3%	7%
	1.00E+08	2%	8%	13%	N/A

Spike Recovery:

o Buffer and cell culture media

Five known concentrations of analyte were spiked into AlphaLISA HiBlock Buffer, AlphaLISA Lysis Buffer, DMEM or RPMI. All samples, including non-spiked diluents were measured in the assay. Note that the analytes for the respective standard curves were prepared in AlphaLISA HiBlock Buffer, AlphaLISA Lysis Buffer, DMEM or RPMI. All other assay components were diluted in AlphaLISA HiBlock Buffer.

Spiked	Antigen Spike Recovery (%)				
AAV9 capsid (VP/mL)	AlphaLISA HiBlock Buffer	AlphaLISA Lysis Buffer	DMEM	RPMI	
1.00E+08	108%	108%	81%	94%	
6.40E+08	88%	81%	104%	90%	
1.00E+09	100%	104%	87%	104%	
1.60E+09	91%	89%	95%	94%	
4.00E+09	93%	98%	103%	100%	

Cell lysates

AAV9 capsid at 1.0E+10 VP/mL was spiked in several dilutions of control SF9 or HEK293 cell lysates not expressing AAV capsids (corresponding to different amount of total protein concentration). All samples, including non-spiked diluents were measured in the assay. Note that the analytes and cell lysates were prepared in AlphaLISA Lysis Buffer (1X). All other assay components were diluted in AlphaLISA HiBlock Buffer

AAV9 (VP/mL)	spiked in SF9 cell lysate (mg/mL of total protein)	% Recovery
	2	59%
	1.5	65%
1.00E+10	1	72%
	0.5	83%
	0.25	82%

AAV9 (VP/mL)	spiked in HEK293 cell lysate (mg/mL of total protein)	% Recovery
1.00E+10	2	88%
	1.5	91%
	1	97%
	0.5	98%
	0.25	91%

As expected, no AAV9 was detected in non-spiked SF9 or HEK293 control cell lysates. Antigen spiking recovery data underlined unbiased AAV9 concentration measurement in cell lysates when total protein concentration was below or equal to 0.5 mg/mL for SF9. In HEK293, the mean recovery regardless of the cell lysate total protein concentration is around 93%, indicating an acceptable impact of the cell lysate. Use caution when analyzing AAV9 content in SF9 cell lysates to ensure that total protein concentration is below 0.5 mg/mL by using dilution with the AlphaLISA Lysis Buffer. At higher SF9 cell lysate total protein concentration, there is an interference that could bias the AAV9 read concentration.

To further investigate recovery data, three known concentrations of analyte were spiked into SF9 or HEK293 cell lysates that are representative of AAVs manufacturing processes at respectively 0.5 and 1.5 mg/ml of total proteins. All samples, including non-spiked diluents were measured in the assay. Note that the analytes for the respective standard curves and samples were prepared in AlphaLISA Lysis Buffer (1X). All other assay components were diluted in AlphaLISA HiBlock Buffer.

	Antigen Spike Recovery (%)		
AAV9 capsid (VP/mL)	SF9 cell lysate (0.5 mg/ml)	HEK293 cell lysate (1.5 mg/ml)	
1.00E+10	96%	102%	
1.00E+09	91%	95%	
1.00E+08	93%	95%	


Specificity:

Cross-reactivity of the AAV9 capsid AlphaLISA Detection Kit was tested using different AAVs capsids in HiBlock Buffer.

The cross reactivities were calculated using concentrations ranging from 0 to 1.0E+11 VP/mL.

Empty AAV Particles	Cross Reactivity (%)
AAV9	100%
AAV1	No
AAV2	No
AAV3B	No
AAV5	No
AAV6	No
AAV8	No

To demonstrate the similar recognition of both full and empty AAV9 capsids, full AAV9-CMV-eGFP and empty AAV9 capsids were analyzed in the assay. A range of AAV9-CMV-eGFP samples with known concentrations in GC/mL were converted into VP/mL using an independent sample quantitation assay.




The AlphaLISA AAV9 capsid detection assay can detect in the same way both full and empty AAV9 capsids but not the other serotypes tested.

Troubleshooting Guide

You will find detailed recommendations for common situations you might encounter with your AlphaLISA Assay kit at: www.revvity.com

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.



The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product's suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF

www.revvity.com

